Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Rhea-AI Summary
Silo Pharma, Inc. files a patent application for SP-26 implantable drug delivery system for time-release and dosage control of ketamine, targeting fibromyalgia. The company believes it could revolutionize chronic pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. announces positive results from a non-GLP small animal dose-ranging study of SPC-15, a potential intranasal treatment for anxiety and PTSD. The study identified the maximum tolerated dose and determined a once-per-day dosing regimen for human clinical trials. The data suggests rapid absorption and good exposure over 24 hours, paving the way for IND submission to the FDA by the end of the second quarter 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. provides a positive update on SP-26, a novel time-released, dose-controlled formulation of ketamine targeting fibromyalgia. Pre-clinical research is ongoing to determine drug release and stability, showing successful loading and encapsulation of ketamine in polymer implants. Structural integrity of the implants is maintained, indicating potential for sustained drug delivery for chronic pain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) announced positive results from a preclinical study showing the effectiveness of its Alzheimer’s disease therapeutic SPC-14 in small animals. The study, conducted in collaboration with Columbia University, demonstrated that SPC-14 was effective in attenuating LH stress, learned helplessness, perseverative behavior, and anxiety in mice. The company is optimistic about the potential of SPC-14 to provide relief to patients and families suffering from Alzheimer’s disease, and plans to update shareholders on the next steps for advancing the therapeutic to a clinical study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company provided an update on its dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD), with the final validation report expected in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) is developing a potential at-home pain relief treatment for fibromyalgia and other chronic pain conditions. The company's dosage and time-release ketamine-loaded implant, designated as SP-26, is advancing through analytical testing and small batch pre-clinical proof of concept extrusion trials in collaboration with Sever Pharma Solutions. The implant formulation will be studied utilizing the subcutaneous injection method, with Silo intending to pursue the FDA’s streamlined 505(b)(2) pathway for approval of SP-26.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) has announced an exclusive license agreement with Medspray Pharma BV for its patented soft mist nasal spray technology to be used with Silo's intranasal therapeutic drug SPC-15. The technology will cover multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia, providing a valuable asset for Silo's research and development of novel therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
-
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range. Collaboration with AmplifyBio, Silo Pharma’s contract research organization (CRO) partner, will conduct a non-GLP study including single ascending dose evaluation and a 7-day repeat intranasal dose toxicity and pharmacokinetic study. The final validation report is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Silo Pharma plans to conduct a human factor study for its targeted prophylactic treatment SPC-15 for PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
Rhea-AI Summary
Silo Pharma plans to submit a pre-IND application to the FDA in Q1 2024 for its SPC-15 intranasal prophylactic for anxiety and PTSD. The company's pre-clinical data show additive benefits in combating stress-induced pathophysiology. Silo Pharma is working with Kymanox for regulatory support and plans to file a pre-IND meeting request with the FDA in early 2024. SPC-15 utilizes metabolic biomarker profiling to inform treatment and prevention of stress-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
FAQ
What is the current stock price of Silo Pharma (SILO)?
The current stock price of Silo Pharma (SILO) is $1.284 as of November 8, 2024.
What is the market cap of Silo Pharma (SILO)?
The market cap of Silo Pharma (SILO) is approximately 5.6M.
What does Silo Pharma, Inc. specialize in?
Silo Pharma specializes in developing novel therapeutics that combine traditional and psychedelic treatments for conditions such as PTSD, fibromyalgia, Alzheimer's disease, and other neurological disorders.
What are Silo Pharma's leading development programs?
Silo's leading programs include SPC-15, an intranasal treatment for PTSD; SP-26, a ketamine-loaded implant for chronic pain; and SPC-14, an intranasal compound for Alzheimer's disease.
Who are Silo Pharma's research partners?
Silo Pharma collaborates with Columbia University and the University of Maryland, Baltimore for its research and development programs.
What recent achievements has Silo Pharma announced?
Recent achievements include the provisional patent filing for SP-26 and the exclusive licensing of SPC-15 from Columbia University.
How does Silo Pharma aim to impact the healthcare industry?
Silo aims to revolutionize the healthcare industry by developing transformative treatments for underserved conditions, merging traditional and psychedelic therapies.
Where can I find more information about Silo Pharma?
You can find more information on their official website at www.silopharma.com and on their social media pages on LinkedIn, X, and Facebook.
What is the significance of Silo Pharma's SP-26 program?
SP-26 is significant as it is a ketamine-loaded implant designed to provide time-release pain relief for conditions like fibromyalgia, potentially being the first at-home approved ketamine-based therapeutic.
What progress has been made with the SPC-15 program?
SPC-15 has shown promising preclinical results for PTSD and anxiety, with the company preparing to submit a pre-IND application to the FDA.
What conditions does Silo Pharma aim to address with its treatments?
Silo aims to address conditions including PTSD, fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
How does Silo Pharma fund its research projects?
Silo Pharma provides the necessary financial resources in collaboration with leading medical universities to advance their research from the clinical stage to commercialization.
Silo Pharma, Inc.
Nasdaq:SILO
SILO Rankings
SILO Stock Data
5.56M
4.48M
4.14%
2.13%
2.88%
Biotechnology
Apparel & Other Finishd Prods of Fabrics & Similar Matl
United States of America
SARASOTA